← Back to Live Feed
Walmart’s stock is up 162% in 5 years. Is it too expensive?
Rolling Out November 20, 2026
Entertainment

Walmart’s stock is up 162% in 5 years. Is it too expensive?

Listen to Story Narration
Click play for AI audio summary
AUDIO

⚡ BLK.news Key Takeaways

Analysts raised targets after a strong quarter, but the valuation debate hasn’t settledWalmart beat Wall Street estimates in its third quarter and several analysts raised their price targets afterward. Walmart’s U.S. comparable sales grew 2.9 percent, but that figure carried about a 125-basis-point drag from Maximum Fair Price pharmacy deflation and shifts from brand-name to generic drugs. Which analysts raised their targets? Analysts expect Walmart’s earnings per share to grow at a compound annual rate of 11.1 percent from fiscal 2026 through fiscal 2029. Walmart’s net income grew from $13.7 billion in fiscal 2021 to $22.3 billion in fiscal 2026, a 63 percent increase.

Analysts raised targets after a strong quarter, but the valuation debate hasn’t settled

Walmart beat Wall Street estimates in its third quarter and several analysts raised their price targets afterward. The stock still fell on Thursday before recovering today.

Sponsored Report

The company now trades near a $1 trillion market value at a price-to-earnings ratio of 46.5. That multiple is roughly double the S&P 500’s 23.3, and it sits at the center of the debate over whether the stock has run too far.

What did Walmart report?

Walmart posted adjusted earnings of 65 cents per share, one cent above the consensus estimate of 64 cents. That figure excludes an after-tax loss of 3 cents per share tied to equity and other investments.

Revenue rose 5.2 percent year over year to $188.835 billion, topping the $187.271 billion consensus. The company also raised its guidance.

Why did the stock drop anyway?

The answer sits inside the pharmacy numbers. Walmart’s U.S. comparable sales grew 2.9 percent, but that figure carried about a 125-basis-point drag from Maximum Fair Price pharmacy deflation and shifts from brand-name to generic drugs.

GLP-1 weight-loss drugs offset part of that, contributing roughly 60 basis points. Strip out health and wellness entirely and comparable sales rose 3.6 percent, a slight acceleration from the prior quarter.

Is the weight-loss drug boost fading?

It appears to be moderating. Prescription volumes are still rising, but the sales contribution from GLP-1 drugs is losing momentum.

BTIG analyst Robert Drbul expects pharmacy pricing headwinds to stay near current levels or increase slightly while the GLP-1 contribution moderates. He also expects improving health and wellness gross margins to cushion the impact.

Which analysts raised their targets?

Five analysts lifted their forecasts after the report while keeping their existing ratings:

Morgan Stanley’s Simeon Gutman, to $135 from $125

Piper Sandler’s Peter Keith, to $138 from $128

TD Cowen’s Max Rakhlenko, to $147 from $125

Truist Securities’ Scot Ciccarelli, to $134 from $114

BTIG’s Robert Drbul, maintained at $140

Walmart traded at about $129.65 on Friday afternoon, within a 52-week range of $102.15 to $135.16.

What’s the case against the valuation?

One market columnist argues the price has outrun the growth. Analysts expect Walmart’s earnings per share to grow at a compound annual rate of 11.1 percent from fiscal 2026 through fiscal 2029.

That column’s argument is that 11 percent growth does not support a 46.5 multiple, and that the ratio is more likely to compress than expand over the next five to 10 years. Compression would pressure the stock even if the business keeps performing well.

What has driven the run so far?

Walmart’s net income grew from $13.7 billion in fiscal 2021 to $22.3 billion in fiscal 2026, a 63 percent increase. The company has added online sales, advertising and subscription revenue to its traditional retail base.

Drbul projects fiscal 2027 net sales of $748 billion, about 6 percent growth, with operating income growing faster than sales. He raised his fiscal 2028 earnings estimate to $3.25 from $3.15.

The quarter was solid. Whether the price already reflects that is the question analysts are still splitting on.